Advertisement

Drugs

, Volume 79, Issue 16, pp 1829–1829 | Cite as

Correction to: Polatuzumab Vedotin: First Global Approval

  • Emma D. DeeksEmail author
Open Access
Correction
  • 269 Downloads

1 Correction to: Drugs (2019) 79:1467–1475  https://doi.org/10.1007/s40265-019-01175-0

The article Polatuzumab Vedotin: First Global Approval, written by Emma D. Deeks, was originally published Online First without Open Access. After publication in volume 79, issue 13, pages 1467–1475 Roche/GCC requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Roche/GCC. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit original author(s) and the source, provide a link to the Creative Commons licence and indicate if changes were made.

The original article has been corrected.

Copyright information

© Springer Nature 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations